|Bid||2,370.75 x 0|
|Ask||0.00 x 0|
|Day's Range||2,322.65 - 2,415.00|
|52 Week Range||1,901.15 - 3,399.90|
|PE Ratio (TTM)||34.62|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.
Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's revenue. The lawsuits were filed against Dr. Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.
Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.